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Abstract
Purpose—Microbubble contrast agents are currently implemented in a variety of both clinical
and preclinical ultrasound imaging studies. The therapeutic and diagnostic capabilities of these
contrast agents are limited by their short in-vivo lifetimes, and research to lengthen their
circulation times is ongoing. In this manuscript, observations are presented from a controlled
experiment performed to evaluate differences in circulation times for lipid shelled
perfluorocarbon-filled contrast agents circulating within rodents as a function of inhaled
anesthesia carrier gas.
Methods—The effects of two common anesthesia carrier gas selections - pure oxygen and
medical air – were observed within five rats. Contrast agent persistence within the kidney was
measured and compared for oxygen and air anesthesia carrier gas for six bolus contrast injections
in each animal. Simulations were performed to examine microbubble behavior with changes in
external environment gases.
Results—A statistically significant extension of contrast circulation time was observed for
animals breathing medical air compared to breathing pure oxygen. Simulations support
experimental observations and indicate that enhanced contrast persistence may be explained by
reduced ventilation/perfusion mismatch and classical diffusion, in which nitrogen plays a key role
by contributing to the volume and diluting other gas species in the microbubble gas core.
Conclusion: Using medical air in place of oxygen as the carrier gas for isoflurane anesthesia can
increase the circulation lifetime of ultrasound microbubble contrast agents.
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1. Introduction
Microbubble contrast agents (MCAs) are currently implemented in many ultrasound
imaging studies to provide enhanced resolution of a vascular network (1–3) as well as to act
as vehicles for therapeutic applications (4,5). These contrast agents are lipid-encapsulated
gaseous microspheres, ranging in diameter from 1–10 μm. Their ability to improve an
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image’s quality is due to the difference in acoustic impedance between their gaseous core
and the surrounding medium. The impedance difference, as well as their compressibility,
causes MCAs to be very echogenic, where even a single microbubble can be detected (5–7).
The nonlinear behavior of MCAs in response to ultrasound pulses allows their scattered
echoes to be separable from tissue, providing a high contrast to tissue ratio. MCAs have
been applied in a wide range of imaging studies including assessing myocardial perfusion
(8,9), imaging blood-perfusion in tumors (10, 11), and molecular targeting of angiogenesis
or inflammation (12–15).
Other applications of microbubble vehicles include acting as therapeutic delivery mediators,
where microbubbles carry a gene or drug on or within their shell (4, 16–18). Microbubbles
can also be applied in conjunction with therapeutic compounds to enhance drug or gene
delivery across the vascular endothelium (6).
The ability of a MCA to either enhance imaging of blood perfusion or act as therapeutic
mediator is maintained only as long as it is freely circulating and intact in the bloodstream,
or intentionally deposited at a localized site. Therefore, if administration is through a bolus
injection, the time window for ultrasound imaging or therapeutics is integrally correlated to
the in-vivo circulation times of the microbubbles. It has been hypothesized that the short in-
vivo and in-vitro lifetimes of MCAs are a rate limiting step for advancing ultrasound
contrast technology as quickly as other contrast imaging modalities, such as x-ray and MRI
(19). Under normal physiological conditions, an injected microbubble’s lifetime is a
function of both compositional and environmental variables. Studies have shown that the
makeup of a bubble’s lipid shell and the content of the gas core effect its lifetime (20, 21),
while environmental factors such as the acoustic waveforms incident on the bubble (22),
dissolved gas concentration in the blood (23,24), and immune response (25) also play
critical roles. Recent attempts to improve the composition of microbubbles include using
higher molecular weight and less soluble filling gasses (21, 26), and altering the chemical
composition of the microbubble’s lipid shell (27,20). Increasing the circulation lifetimes
would improve the ability to perform consistent imaging studies over time with a bolus
injection, as well as improve the window in which both diagnostic and therapeutic
applications can be applied.
One possible method to improve the environmental conditions for injected MCAs during
studies in anesthetized animals is by changing the dissolved gas concentration of an animal’s
blood. It is well known that the gas saturation in the medium surrounding the microbubble
affects the gas core’s dissolution rate (27–29). Early studies with first generation contrast
agents demonstrated that MCAs circulating in dogs that inhaled different anesthesia carrier
gases had different circulation times (23, 24). These previous studies examined two albumin
shelled agents, Albunex and Optison, and observed circulation persistence for different
ratios of two common selections for anesthesia carrier gas: medical air and pure oxygen. In
both studies, the imaging contrast provided by these two types of MCAs was diminished by
the use of pure oxygen as a carrier gas compared with the contrast provided by the same
MCA type in the same animal breathing medical air as the carrier gas.
In this paper we extend these early studies from albumin-shelled contrast agents to newer
lipid-shelled perfluorocarbon-filled contrast agents. Additionally, we examine the effects of
inhaled anesthesia gas on injected MCAs in a rodent model. Rodents are commonly used as
preclinical models of cancer and other diseases, and as such, are frequently selected as
subjects in ultrasound contrast imaging studies. The purpose of this study was to elucidate
the extent and significance of the relationship between anesthesia carrier gas composition
and MCA circulation lifetime in rats.
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2. Results and Discussion
2.1. The effect of carrier gas composition on MCA lifetime in vivo
Six imaging studies were completed for each animal, with each study consisting of a single
bolus injection of contrast. Circulation times, obtained from intensity curves (Fig. 1), were
compared for medical air and oxygen. A statistically significant difference (p < 0.05) was
observed for MCA circulation time as a function of anesthesia carrier gas in four out of five
animals (Fig 2). Circulation time in the cases for which the data was not significant
illustrated the same trend as in the other animals. Administering medical air as the
anesthesia carrier gas caused the contrast agent half-life to be an average of 1.8 ± 0.1 times
longer than when using pure oxygen. A greater difference was observed when examining
time to 25% peak intensity; the t0.25Imax was 2.2 ± 0.2 times longer when the animal was
breathing medical air compared to breathing pure oxygen.
2.2. Relationships between carrier gas and physiology
Dissolved blood oxygen and carbon dioxide gas partial pressures were measured in four
animals to observe any partial pressure differences between animals breathing pure oxygen
and medical air (Table 1). The largest effect of carrier gas on these variables was with pO2,
as the average value was over six times higher when breathing oxygen compared to medical
air. The sum of partial pressures (Σpi) indicated a greater degree of ventilation/perfusion
mismatch for oxygen-breathing rats than for air-breathing rats, as may be expected (30,31).
One might hypothesize that the longer circulation times may be due to vasculature changes
induced by the different inhaled anesthesia carrier gases. However, based on the measured
blood gas values, shown in Table 1, it does not appear that vascular changes are contributing
to the increased MCA circulation lifetime. CO2 partial pressure levels have been shown to
be related to changes in vasculature dilation (32), but these values stayed relatively constant
regardless of the administered carrier gas. Other factors that could potentially influence
circulation time, such as breathing rate, heart rate and body temperature were investigated.
Preliminary studies (data not shown) showed no correlation between breathing rate, heart
rate and body temperature and circulation times.
2.3. Simulations of MCA circulation time
To gain physical insight, we modeled microbubble dissolution times in blood by considering
pure diffusion (no convection) of the different gas species into and out of the bubbles, as
others have reported previously (33,34). Equations (1) and (2) were solved numerically
using the Newton-Raphson method and MATLAB software (MathWorks, Natick, MA) for a
2-, 5- and 10-μm diameter microbubble initially filled with pure perfluorobutane (PFB) and
suddenly immersed in blood. Blood gas (O2, N2, H2O and CO2) partial pressure values were
taken from Table 1 to simulate oxygen versus air as the carrier gas. The surface tension was
set to 0 mN/m (28), and the hydrostatic pressure was set to 760 mmHg.
Figure 3 shows the simulation results for the two carrier gases. Theory predicted that a 2-μm
diameter microbubble survives approximately 3.2 times longer when medical air is used
instead of oxygen (Fig. 3). As the diameter is increased to 10 μm, the microbubble lifetimes
are predicted to be 126 seconds for oxygen-breathing and 409 seconds for air-breathing,
which is in good general agreement with the experimental in vivo imaging data. We should
note that the simplified model is limited when making direct comparisons to in vivo contrast
persistence data. Inspection of the microbubble contents over time provided an explanation
for the extended lifetime (Fig. 4). Initially, the blood gases rapidly diffused into the
microbubble just as PFB, which has a much lower solubility and diffusivity in water, slowly
dissolved away. The inrush of blood gases resulted in rapid microbubble growth.
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Microbubble growth could not be measured acoustically here due to the complexity of the in
vivo backscattered signal. However, microbubble growth has been predicted and measured
as an increase in ultrasound attenuation in a more idealized system by Sarkar et al. (35,36).
The presence of nitrogen extended the growth phase by not only adding to the volume, but
also diluting the other gas species, resulting in greater accumulation of the other blood gases
and reduction in the rate of PFB efflux. After a short time, the microbubble was mainly
composed of blood gases, and PFB contributed only slightly to the total volume. Eventually,
all gases began to efflux from the microbubble as PFB dissolution continued and the partial
pressures of O2, N2 and CO2 in the gas core exceeded the partial pressures in the
surrounding blood. The dissolution rate was accelerated for the oxygen-carrier case owing to
the greater degree of ventilation/perfusion imbalance. The sum of the partial pressures for
oxygen-breathing (653 mmHg) was much lower than for air-breathing (740 mmHg). Since
the ambient pressure was approximated to be 760 mmHg, the oxygen-breathing case
represented a greater deviation from equilibrium and therefore a greater driving force for
microbubble dissolution.
We should note that the simplified model is limited when making direct comparisons to in
vivo contrast persistence data. The calculation ignores the gas permeation resistance of the
shell and assumes a constant surface tension (although near zero), which may not be true
during the multiple regions of growth and dissolution that bubbles would experience (37).
Additionally, the calculations only take into account a single bubble under no-flow
conditions. It is possible that a population of bubbles is more stable than a single bubble.
The overlapping diffusion zones between neighboring microbubbles will influence their rate
of dissolution, and there may be more subtle effects at play such as Ostwald ripening. These
assumptions, along with activity of other clearance mechanisms like the reticuloendothelial
system (RES), could account for observed circulation times being longer than the model
predicts. Despite the limitations of the model, it clearly illustrates different responses due to
different gases which agrees with experimental data.
3. Conclusions
A relationship between the anesthesia carrier gas and the in-vivo lifetime of injected MCAs
was observed within the five animals tested in this study. Each animal was administered
three doses of MCAs under each type of carrier gas - medical air and pure oxygen - and the
persistence of these contrast agents was monitored following injection. Half-life values and
time to 25% intensity were calculated. Medical air was found to significantly increase the
circulation time of ultrasound MCAs. The numerical results obtained using a model obeying
classical Fickian diffusion with multiple gas species aligned with the experimentally
measured values, suggesting that diffusion plays a key role in the reduced circulation time of
injected MCAs in pure oxygen-breathing animals. The effects of diffusion for the oxygen-
breathing case are manifest as an increased driving force (i.e., ventilation/perfusion
mismatch) and more rapid mass transfer (i.e., absence of an inert ‘filling’ gas) for
microbubble dissolution. This study illustrated that a simple change of an anesthesia carrier
gas has the potential to improve the efficacy of ultrasound studies, both imaging and
therapeutic.
4. Experimental
4.1. Gas Diffusion Model
To investigate whether gas diffusion could account for differences in MCA lifetime, a
mathematical model previously developed by Kwan and Borden (37) was employed which
predicts the size of a microbubble suddenly immersed in a multi-gas environment, such as a
PFB microbubble injected into blood. This model assumes that each gas acts independently
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to equilibrate at the gas/liquid interface and diffuse along its own chemical potential (partial
pressure) gradient. All gases contribute to the total pressure and volume of the MCA gas
core. Gas diffusion occurs through a stagnant aqueous layer equal in thickness to the
microbubble radius (i.e., it is a purely diffusing sphere). Because the animal was breathing,
the impact of the microbubble injection (~2 μl gas) on the dissolved gas contents of the
blood pool was considered negligible. A set of coupled, nonlinear differential equations
results from (i) a species balance over the microbubble, (ii) the diffusion equation, (iii) the
Laplace pressure equation and (iv) the ideal gas law. Applying a finite difference method,
the set of equations is discretized to the following form:
(1)
(2)
where N is the total number of gas species; τ is the numerical time step; R is the
microbubble radius; σ is the microbubble surface tension; PH is the hydrostatic pressure; B
is the universal gas constant; T is temperature; ni is the moles, Di is the diffusion coefficient,
KH,i is Henry’s constant, P∞,i is the partial pressure at saturation, and fi is the ratio of the
bulk dissolved gas content to that at saturation, each of component i. Solving equations 1
and 2 numerically allows prediction of the growth and dissolution of a microbubble subject
to the simultaneous influx and efflux of different gas species as the system tends toward
thermodynamic equilibrium, which occurs when the partial pressures in the gas core and
surrounding medium are equal for all species. A variable time step was used to ensure that
the moles inside the microbubble did not become negative. To determine the number of
moles in the bubble, a forward wind difference method was applied, as seen in equation (1),
which is solved step-wise. Equation (2) is nonlinear and was solved using a Newton-
Raphson method (100 iterations). Finally, it should be noted that the model is limited in that
it neglects the effects of convection in the surrounding medium, variations in blood gas
concentrations and pressure as the microbubble passes through the venous-arterial circuit,
and effects of the encapsulating shell, such as gas permeation resistance and viscous and
elastic terms accounting for lipid monolayer expansion, break-up, compression, buckling
and collapse.
4.2. Animal preparation
Animals were handled according to National Institute of Health guidelines and our study
protocol was approved by the UNC Institutional Animal Care and Use Committee. Five
female Sprague-Dawley rats (Harlan; Indianapolis, IN) were imaged throughout the course
of this study. Before imaging an animal, it was first anesthetized in an induction chamber by
introducing an aerosolized 5% isoflurane - oxygen mixture. Once sedated, the animal was
removed from the induction chamber, the isoflurane concentration was reduced from 5% to
2% and then maintained via mask delivery. Its abdomen was shaved with an electric clipper
and a depilating cream was applied to the animal’s skin to dissolve any remaining hair that
would interfere with the ultrasound image. A 24 gauge catheter was then inserted into the
animal’s tail vein for the administration of MCAs. The animal was placed in dorsal
recumbency on a heating pad, and ultrasound coupling gel was placed between the imaging
transducer and the animal’s skin to ensure the quality of signal transmission.
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4.3. Contrast agent preparation and administration
A lipid mixture (1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC); 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt)
(DSPE- PEG2000)) (Avanti Polar Lipids) was prepared using a 9:1 molar ratio, similar to a
previously described method (20). Briefly, lipids were dissolved in chloroform, dried, and
dissolved into a buffer solution of PBS. The lipid solution was then transferred into vials,
which were then evacuated and filled with decafluorobutane gas. Vials were shaken with a
Vialmix shaker (Bristol-Myers Squibb Medical Imaging, North Billerica MA) for 45
seconds prior to injection. MCAs were withdrawn directly from the vial with the vial vent
connected to a bag filled with decafluorobutane, to ensure that no air entered the headspace
of the vial. 25 μl of MCAs were administered through the tail vein, followed immediately
by a 200 μl flush of sterilized saline.
4.4. Image acquisition
The kidneys of the rats were selected as the imaging location for this study because of their
proximity to the skin’s surface and the high concentration of vasculature. The clinical
system used to acquire all ultrasound images in this study was an Acuson Sequoia 512
(Siemens – Mountain View, CA). B-mode images were collected at 14 MHz using a linear
array transducer (Model # 15L8). Contrast agents were imaged in CPS mode operating at 7
MHz and a mechanical index of 0.18. CPS provides a high contrast-to-tissue ratio while
being minimally destructive to MCAs. Video data collection started prior to a bolus
injection of MCAs, and continued for up to 20 minutes to allow a majority of the
microbubbles to be cleared by the animal. If there were still MCAs visibly circulating in the
image after 20 minutes, data collection was prolonged to accommodate the longer MCA
persistence. Data by Killam et al. (38) showed that after Optison injection into canines, the
octafluoropropane was eliminated after a mean residence time of 38–46 seconds. As our
model clearly shows, PFB rapidly dissolves from the microbubble and is replaced by the
blood gases. It is therefore reasonable to assume that PFB is eliminated from the blood
between contrast agent injections, which are 20 minutes apart. After the completion of all
measurements for an animal, the imaging study would be closed and the data exported from
the ultrasound system in DICOM format. These files were later analyzed offline in
MATLAB. Multiple imaging sequences were obtained of each anesthetized rat. An imaging
sequence included the collection of two runs of data, one breathing oxygen and one
breathing air, each beginning with an injection of MCAs and lasting until contrast agents
were no longer visibly circulating. The order of carrier gas administration was randomized
for all the animals. After the completion of the first run, the anesthesia carrier gas was
changed and the animal was given ten minutes to acclimate to this new carrier gas before
initiating the second imaging sequence (24). The imaged sequence was repeated two more
times to obtain a total of three imaging sequences for each carrier gas.
4.5. Monitoring physiological changes
Blood samples were collected to determine the extent of the relationship between dissolved
blood gas partial pressures of oxygen, nitrogen, and carbon dioxide and anesthesia carrier
gas. Arterial blood samples were obtained from the tail and tested immediately after
collection in a pH/blood gas analyzer (Chiron Diagnostics, Emeryville, CA, USA). Each
sample was collected only after the animal had acclimated to the anesthesia carrier gas being
tested.
4.6. Measuring microbubble circulation time
All video data were exported from the ultrasound system and imported into MATLAB for
analysis. Regions of interest (ROI) were defined around the perimeter of the kidney of each
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animal, and the mask applied to every frame of data. All data were examined to ensure there
were no gross movements in tissue to cause inaccuracies in the ROI. The mean pixel
intensity within the ROI was computed and plotted as a function of time. An example of this
data is displayed in Figure 1. To compute a pre-contrast baseline value, the mean pixel
intensity of the ROI was averaged prior to the bolus injection of MCAs. After the MCAs
were injected, the mean pixel intensity would rise sharply to a single peak value as the bolus
entered through the ROI, then decline as the bubbles became distributed throughout the
animal’s body and cleared from the system. As the population of injected MCAs began to
decline, the grayscale pixel intensity in the ROI would also decay steadily from the initial
peak down to the original baseline value. Using MATLAB, a 4th order interpolation
polynomial was fit to the data following the peak value in the run.
Two metrics were used to quantify the circulation times of the injected MCAs: half-life, and
time to 25% intensity ( t0.5Imax and t0.25Imax respectively). These were defined as the
difference between the injection time (as determined by the highest mean intensity value in
the dataset) and the times at which the data had dropped to the points either halfway to
baseline (t0.5Imax) or 75% of the way to baseline (t0.25Imax) (25).
Measurements were repeated three times for each type of carrier gas on each animal to
determine the effect of anesthesia carrier gas. These MCA circulation times for the two
types of gases were compared between each animal. A paired two-sample Student’s t-test
was used to validate the statistical significance of the difference in circulation times of the
injected MCAs between the two types of carrier gas.
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A comparison of intensity curves obtained from animal 3 while the breathing air compared
to breathing oxygen is shown. The differences between the intensity curves is representative
of results seen in all animals.
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Side by side comparison of the average injected MCA circulation times for each animal. A)
average half-life and B) average time to 25% for each animal inhaling the respective
anesthesia carrier gases. The average circulation times when an animal was breathing
isoflurane carried by medical air were significantly longer in most animals (* indicates
p<0.05).
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Simulated response of a PFB microbubble suddenly immersed in arterial blood. The
dissolved gas parameters used in these simulations, summarized in Table 1, were based on
measured values. Microbubble diameter was normalized by the initial value shown.
Mullin et al. Page 12














Simulated response of a PFB microbubble suddenly immersed in arterial blood. The
dissolved gas parameters used in these simulations, summarized in Table 1, were based on
measured values. Molar contents of each gas are plotted versus time for (A) medical air and
(B) oxygen as the carrier gas.
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